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Background: An increase in circulating platelets, or thrombocytosis, is recognized as an independent risk factor of
bad prognosis and metastasis in patients with ovarian cancer; however the complex role of platelets in tumor
progression has not been fully elucidated. Platelet activation has been associated with an epithelial to mesenchymal
transition (EMT), while Tissue Factor (TF) protein expression by cancer cells has been shown to correlate with
hypercoagulable state and metastasis. The aim of this work was to determine the effect of platelet-cancer cell interaction
on TF and “Metastasis Initiating Cell (MIC)” marker levels and migration in ovarian cancer cell lines and cancer cells
isolated from the ascetic fluid of ovarian cancer patients.
Methods: With informed patient consent, ascitic fluid isolated ovarian cancer cells, cell lines and ovarian cancer spheres
were co-cultivated with human platelets. TF, EMT and stem cell marker levels were determined by Western blotting, flow
cytometry and RT-PCR. Cancer cell migration was determined by Boyden chambers and the scratch assay.
Results: The co-culture of patient-derived ovarian cancer cells with platelets causes: 1) a phenotypic change in cancer
cells, 2) chemoattraction and cancer cell migration, 3) induced MIC markers (EMT/stemness), 3) increased sphere formation
and 4) increased TF protein levels and activity.
Conclusions: We present the first evidence that platelets act as chemoattractants to cancer cells. Furthermore, platelets
promote the formation of ovarian cancer spheres that express MIC markers and the metastatic protein TF. Our results
suggest that platelet-cancer cell interaction plays a role in the formation of metastatic foci.
Keywords: EMT, Coagulation, Metastasis initiating cells, Ascites, N-Cadherin, E-Cadherin, CD44Background
Ovarian cancer is the deadliest gynecological cancer,
causing around of 15,000 deaths in the USA this year
[1]. Despite clinical advances, ovarian cancer continues
to be a poorly understood disease with an unfavorable
prognosis, principally due to late stage diagnosis when* Correspondence: gowen@bio.puc.cl
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unless otherwise stated.the cancer has already disseminated throughout the peri-
toneum [2]. The current theory of cancer progression
proposes that from the total population of cancer cells
within a primary tumor, only a small sub-population has
the capacity to migrate, survive in isolation and establish
secondary tumors within distant organs [3]. Metastasis
Initiating Cells (MICs) are characterized by their en-
hanced chemoresistance, low metabolic rate, possessing
“stemness”, for having undergone Epithelial-Mesenchymal
Transition (EMT) and their enhanced capacity to generate
metastatic foci. Cancer cell stemness (also known asl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cancer cells that are normally associated with physio-
logical stem cells and whose presence associate with
enhanced tumor-forming capacity in xenograft assays and
increased chemoresistance [4] . These markers are numer-
ous and differ depending on the tissue origin, however for
ovarian cancer, one of the most reported examples is
increased CD44 expression [5,6]. EMT, the conversion of
epithelial cells to a more stromal or mesenchymal pheno-
type, is believed to be a fundamental event by which the
cancer cell acquires migratory and invasive properties [7,8].
This event has been associated with lower E-Cadherin ex-
pression and enhanced N-Cadherin and vimentin levels
[9]. The transcription factors Twist, Snail and Slug are
known to promote EMTand cause the down regulation of
E-Cadherin [10-12] As an in vitro model of MICs, under
special culture conditions a heterogeneous population of
cells can give rise to three-dimensional cancer spheres
(cell clusters) which present enhanced expression of CD44
and display the capability of anchorage-independent
growth [13].
Cancer patients have long been reported to present ab-
normal risk of thrombosis that correlates with the pro-
gression of the disease [14-16]. High platelet counts are
prevalent in 31-42% of primary epithelial ovarian cancers
and this correlated with significantly worse prognosis.
[17-19].
It has been speculated that platelets may contribute to
tumor metastasis through EMT induction [20], immune
system evasion, adhesion to endothelial layer, and angio-
genesis and vascular remodeling [21].
A further protein associated with cancer metastasis is
Tissue factor (TF). This transmembrane receptor and
initiator of the extrinsic coagulation pathway is not nor-
mally expressed in the vascular lumen, but makes con-
tact with the circulatory system only upon vascular
injury, resulting in clotting activation [22]. It is widely
reported that many cancer types overexpress functional
TF on the cell membranes and also in tumor derived
microparticles, thus being responsible for enhanced
coagulation and invasion [23-26].
Taken together, accumulating evidence is correlating
platelet function with increased metastasis and poorer
patient survival. However, to date, the effect of platelets
on TF levels have not been described, neither are the
levels of this protein during the acquisition of a MIC
phenotype. Considering that ovarian cancer metastasis
occurs mainly within the peritoneal cavity as a result of
the accumulation of cancer cells in the ascites, the goal
of the present work is to evaluate the effect of platelet
interaction with ovarian cancer cells, regarding pheno-
type, TF and EMT associated protein levels and bio-
logical function. Herein, we present evidence that




Ovarian ascites samples were obtained from the partici-
pating hospitals; Hospital Clínico Pontificia Universidad
Católica de Chile (Santiago, Chile), Hospital Sótero del
Río (Santiago Chile), Hospital Gustavo Fricke (Viña del
Mar, Chile), Fundación Arturo López Pérez (Santiago,
Chile). The cancer type and stage are included in Table 1.
Human cancer cells were isolated from ovarian cancer
ascites as previously reported [27-29]. Primary cultured
cells in passage 2 were typically used for all experimen-
tation. In the case of the benign ovarian fibrothecoma
and the benign ovarian mucinous cystadenoma, cells
were obtained from a peritoneal washing with physio-
logical solution at 37°C prior to surgery. Platelets were
obtained from healthy volunteers not taking medication
that affects platelet function. All experiments and use of
human samples were performed in accordance with the
Declaration of Helsinki. Ethical committee approval was
obtained from each participating hospital and regional
health board. These include: the ethical committees of
the Faculty of Medicine at the Pontifical Catholic Uni-
versity of Chile; Foundation Arturo Lopez Perez,
Santiago Chile; the South Eastern Metropolitan Medical
Service (SSMSO, Santiago de Chile); The Eastern Metro-
politan Medical Service (SSMO, Santiago de Chile); the
Quillota Medical Service (Region V, Chile). Informed
written consent was obtained from all patients and
blood donors.
Reagents
Insulin (SigmaAldrich, St. Louis, MO, Cat N° I2643-
25MG), FGFb (Invitrogen Life Technologies, Carlsbad,
CA, Cat N° AA 10–155, EGF (ProSpec, Ness Ziona,
Israel, Cat N° CYT-217), PGE1 (SigmaAldrich, St. Louis,
MO, Cat N° P5515). Human antibodies: CD44 (Santa
Cruz Biotechnology, Santa Cruz, CA, Cat N° sc-7297),
Tissue Factor (Calbiochem, San Diego, CA, TF9-10H10
(western-blotting), and American Diagnostica, Stamford,
CT, Cat N° 4509 (flow cytometry)), N-Cadherin (Invitro-
gen Life Technololies, Carlsbad, CA, Cat N° 33–3900),
E-Cadherin (Cell Signaling, Technology, NY, Cat N°
24E10), Histone 3 (Cell Signaling, Technology, NY, Cat
N° 9715), Integrin β3 (Cell Signaling CD61, Technology,
NY ,Cat N° 555753), IgG1 mouse (Cell Signaling, Technol-
ogy, NY, Cat N° 555749), Vimentin (Millipore, Technol-
ogy, NY, Cat N° MAB3400), Alexa fluor 555 (Invitrogen
Life Technologies, Carlsbad, CA, Goat Anti-Rabbit IgG
(H + L),Cat. N°: A-21428), Alexa fluor 488 (Invitrogen Life
Technologies, Carlsbad, CA, Anti-Mouse IgG, IgM (H+ L)
Cat N° A-10680), HRP-conjugated anti-rabbit secondary




1 IV Ovarian serous papillary Primary
2 II Ovarian endometrioid
adenocarcinoma
Primary
3 II Ovarian serous papillary
cystadenocarcinoma
Primary
4 IIIc Primary peritoneal
carcinomatosis
Primary
5 IIIc Ovarian serous
cystadenocarcinoma
Primary
6 IIIc Ovarian endometrioid
adenocarcinoma
Relapse
7 N/A Ovarian benign
fibrothecoma
Primary
8 IIIc Ovarian mucinous
cystadenocarcinoma
Primary
9 IIIc Ovarian mucinous
cystadenocarcinoma
Primary
10 N/A Ovarian mucinous
cystadenoma
Primary
11 IIIc Ovarian serous papillary
cystadenocarcinoma
Primary




13 IIIc Ovarian adenocarcinoma
(unspecified)
Primary
14 IIIc Ovarian adenocarcinoma
(unspecified)
Relapse
15 IIIc Ovarian serous papillary Primary




17 IIIc Ovarian serous
cystadenocarcinoma
Primary
18 Ovarian serous papillary Primary
Orellana et al. BMC Cancer  (2015) 15:290 Page 3 of 15antibody (Biorad, Goat Anti-Rabbit IgG (H+ L)-HRP
Conjugate; Cat. N°170-6515, USA) and β-Actin (Sigma
Aldrich, St. Louis, MO, Cat N° A5060).
DNase I (Invitrogen Life Technologies, Carlsbad, CA),
RNAse H, dNTP mix, EDTA, DTT, Tris–HCl KCl,
MgCl2 were all purchased from Invitrogen Life Tech-
nologies, Carlsbad, CA. Fast SYBR green master mix was
bought from Applied Biosystems, USA (Cat no. 4385612).
Nuclease free water was purchased from Winkler,
Santiago, Chile. Factor VIIa, Factor X, chromogenic sub-
strate “Spectrozyme FXa”, TFPI-1 (222B, 526, 526 and
4900 American Diagnostica, Stamford, CT, respectively),
Low Attachment plates (Corning, NY Cat N° 3471),
Fluoromount (Electronic Microscopy Science, Hatfield,
PA, Cat N° 17984–25) and Boyden chambers (Corning,
Cat N° 3458), phototgraphic film (Thermo Scientific™CL-XPosure™ Film; Cat. N° PI-34091), Ponceau-S red
stain (Sigma Aldrich, St. Louis, MO), Hoechst (Invitro-
gen Life Technologies, Carlsbad, CA, Cat N° H1399)
and Fluoromount (EMS 17984–25). Primers, listed in
Table 2, were purchased from IDT, USA.
Extraction of human platelets
Venous blood (64 mL) was collected from healthy volun-
teers (not taking anti-platelet drugs) in ACD-A (1:10,
vol/vol). After centrifugation (9 minutes at 200 g), the
top two-thirds of platelet-rich plasma (PRP) was re-
moved and re-centrifuged (9 minutes at 2700 g). The
pellet was washed in buffer (137 mM NaCl; 2.68 mM
KCl; 11.9 mM NaHCO3; 0.36 mM Na2HPO4x2H2O;
2 mM MgCl2, [pH 6.2]) containing prostaglandin E1
(PGE1) (120 nM), then centrifuged twice (200 g for 9 mi-
nutes) to remove residual leukocytes. Leukocyte contam-
ination was evaluated by fluorescence microscopy using
propidium iodide as a nuclear stain. Leukocytes counts
were always less than 1x105 platelets. All centrifugation
steps were performed at 4°C. Platelet concentration was
determined using the Coulter Particle Counter WS-
Z1DUALPC. Co-culture of human washed platelets and
ovarian cancer cells. Human platelets were centrifuged
(9 minutes at 2700 g) at 4°C, supernatant was discarded
and the pellet was suspended in 3 mL of DMEM F12 5%
charcoal treated serum medium at 37°C. Platelet-
containing medium was added to the culture dish (final
concentration 150,000 platelets/μL) containing already
seeded cell lines A2780, UCI101, SKOV3 and the human
ascites primary culture. After 6 or 12 hours of incuba-
tion, the cell monolayer was washed three times with
PBS to eliminate the supernatant platelets.
Ovarian cancer sphere formation assay
200,000 ovarian cancer cells (UCI101), were cultured in
6 well low attachment plates in DMEM/F12 medium
supplemented with FGF 50 μg/mL; EGF 0.2 mg/mL; in-
sulin 5 g/mL. Every 48 hours 1 mL of supplemented
medium with or without 150,000 platelets/μL was added.
After 7 day of culture, medium was passed through a
100 μm strainer to collect ovarian cancer sphere clusters
(the size of spheres typically ranges 40–100 μm in diam-
eter) [30]. To be sure that we excluded aggregates,
spheres were recuperated, counted and analyzed by flow
cytometry. Spheres were counted by microscopy at 20X,
using 17 fields with covered the entire plate.
Scratch and migration assay
UCI101 and SKOV3 cells were cultured in standard tis-
sue culture plates until 80% confluence, and then a verti-
cal wound (scratch) was introduced through the cell
monolayer using a fine pipette tip. The culture medium
was replaced with fresh DMEM/F12 containing 5%
Table 2 Sequence of the primers used for mRNA levels
analysis
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platelets (150,000 platelets/μL). Wound closure was
assessed by photography at 12, 24 and 48 hours and
quantified using the Image J software.
Chemoattractant effect was further analyzed using
Boyden chambers. To these chambers, 7.5 x 104cells
were seeded in the upper well in 400 μL of DMEM/F12
5% charcoal treated serum medium, while the lower well
was filled with the same medium. Platelets were added
in the upper or the lower well (150,000 platelets/μL) as
stated in the figure legends. Corresponding controls
without platelets were performed. After 24 hours of in-
cubation at 37°C and 5% CO2 the membrane of the
upper chamber was cut and fixed with methanol at −20°C
during 20 min. The membranes were washed 3 times with
PBS, and then the endogenous peroxidase was inhibited
by using hydrogen peroxide for 10 min at darkness. Then
membranes were blocked for 2 hours with PBS-BSA 1%
and incubated with vimentin antibody (1:100) over night.
Membranes were washed 3 times with PBS and revealed
with immunocytochemistry kit (DAKO) according to the
procedures manual. Finally we counted the number of
cells that migrated through the membrane using a light
microscope.
Flow cytometry analysis
With full ethical committee approval, during surgery the
ascites is extracted through a small puncture made in an
avascular zone of the peritoneum to minimize contamin-
ation with blood. Once the liquid is extracted from the
cavity, the rest of the abdomen is opened for surgery.
Cases of hemorrhagic ascites were not used in this study.For analysis of human ovarian ascites samples (all sam-
ples came from cancer patients post-menopause), 1 mL
of fluid was collected and centrifuged during 3 min at
3000 rpm. Then the supernatant was centrifuged for
9 min at 2700 g and the pellet was resuspended in
300 μL of 1% BSA and separated into 3 aliquots. The
first was used as a negative control. The second tube
was incubated with 5 μL of Anti CD61 and 5 μL of nor-
mal mouse IgG; and the third tube was incubated with 5
uL of Anti CD61 and 5 μL of Anti CD62P. After 25 min
in darkness and room temperature the tubes were thrice
washed in PBS. Samples were read in the flow cytometer
(ACCURI C6), and the data analyzed using the software
C Flow Sampler. For the co-culture of platelets and can-
cer cells, the platelets were added over the cells for
15 min. Later 1 mL of medium was centrifuged for
9 min at 2700 g and the pellet suspended in PBS-BSA
1%. Then the platelets were analyzed for CD61 and
CD62P markers. For TF analysis 5 μL of TF antibody
was added for 25 min at room temperature, followed by
1 μL (from a previous 1/10 dilution) of Alexa 647 anti-
mouse for 20 min in darkness. Cells were subsequently
washed for flow cytometer analysis.
Western blot analysis
120,000 cells were seeded in 6 cm plates. Total proteins
from cell lines were extracted using 150 mM Tris–HCl
lysis buffer containing NaCl 1.5 M, and Triton X-100
0.5%. Lysed cells were left for 20 minutes on ice, centri-
fuged at 4,000 rpm for 5 minutes at 4°C, then cells are
sonicated and centrifuged at 4,000 rpm for 5 minutes at
4°C. The resulting protein content of the supernatant
was determined by the Bradford method and stored at
−80°C. Equal amounts of protein (100 μg/lane) were sep-
arated using 12% SDS-PAGE or 10% SDS-PAGE under
reducing conditions and transferred to nitrocellulose
membranes (Biorad, Hercules, CA), blocked with BSA
3% in TBS-0.1% Tween-20 and incubated overnight at
4°C with the primary antibodies anti- E-Cad (1:500),
anti-N-Cad (1:500), and anti-CD44 (1:500). For TF ana-
lysis we blocked with 5% nonfat dry milk in TBS-0.1%
Tween-20 buffer (TBS-T) and incubated overnight at
4°C with anti- TF (1:500). For β-actin (1:3000) analysis
and Histone H3 (1:1000) we blocked with 5% nonfat dry
milk in PBS-0.1% Tween-20 buffer (PBS-T) both used as
load control. All the antibodies were diluted in blocking
buffer. The membranes were washed three times for five
minutes in TBS-T buffer, incubated with HRP-conjugated
anti-rabbit secondary antibody for two hours at room
temperature and developed with chemiluminescence re-
agent (Pierce ECL Thermo Scientific, US.). Membranes
were exposed to phototgraphic film, with equal protein
loading confirmed with Ponceau-S red staining. Images
were scanned at 16-bit/600 dpi resolution with an Epson
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as TIFF files and calibrated to an optical density scale. The
integrated optical density of bands was quantitated using
the Image J v.1.47 software. The optical densities were
expressed as the ratio of treatment/control.
Immunofluorescence
From ascites extracted with informed consent from
ovarian cancer patients, 1 mL was placed onto a cover-
slip and allowed to evaporate at room temperature. The
slide was fixed with methanol at −20°C during 20 min
before blocking with 2% BSA for 30 mins. Antibodies
against CD42b (reacts with GpIb specific for platelets,
1:250, and vimentin (cancer cells, 1:1000,) were applied
overnight in the dark at 4°C. The slide was washed 3
times with PBS and the secondary antibody (anti-mouse
Alexa 488) or anti- rabbit (Alexa Fluor 555, Goat Anti-
Rabbit IgG (H + L)) were used at a dilution of 1:10000
for 1 hour in the dark at room temperature. Cells were
washed 3 times with PBS and then stained with Hoechst
(1:50000) for 4 minutes. The slides were mounted in
Fluoromount and observed under a NIKON Eclipse
E200 fluorescent microscope.
Pro-coagulant activity assay
After 24 hours of co-culture cells were washed with
PBS, detached using trypsin and washed three times
again to remove remaining platelets. Then, 5 x 104 cells
were placed into 96 wells plate. The cells were incubated
in presence of FVIIa (1U mL−1), FX (1,2 U mL−1), CaCl2
(25 mM) and Spectrozyme FXa (1 mM) for 30 min.
TFPI-1 (0.5 ug/ml) was added 30 minutes prior to the co-
agulation factors. Optical density was read in microplate
spectrophotometer (EPOCH, Model 251450, BioTek,
USA) at 405 nm.
RNA extraction
150,000 ovarian cancer cells were seeded for these ex-
periments. Total RNA was extracted from co-cultures of
ovarian cancer cell lines and primary cultures of ascites
using Trizol (Invitrogen Life Technologies, Carlsbad,
CA). Concentration and purity was evaluated through
optic density at 260 nm and the 260 nm/280 nm ratio
(EPOCH, Model 251450, BioTek, USA). RNA was sus-
pended in nuclease free water and its integrity confirmed
by the presence of intact 18 s and 28 s ribosomal sub-
units by agarose gel electrophoresis.
RT-PCR
2 μg of total RNA was treated with DNase I (1U μL−1)
for 10 min at 25°C to eliminate possible contamination
with genomic DNA. The reaction was stopped with 1μL of
EDTA (25 mM, pH 8) at 65°C for 15 min. The reverse tran-
scriptase reaction was performed using a mix composed of2 μL of random primers (50 ng μL−1, Invitrogen Life Tech-
nologies, USA) was added to 1 μL of dNTP mix (ATP, CTP,
GTP, TTP, 10 mM) , and incubated at 65°C for 5 min. Sub-
sequently, 4 μL of reverse transcriptase buffer 5 X (250
mM Tris–HCl pH 8.3; 375 mM KCl, 15 mM MgCl2), 2 μL
of 0.1 M DTT and 1 μL of Superscript reverse transcriptase
II and RT-RNAse H- (200 U μL-1) were added and incu-
bated at 25°C for 10 min, followed by 50 min at 42°C for,
and finally 15 min at 70°C in an Axygen Maxygene
thermocyler.
Real time PCR
To evaluate mRNA levels in cell lines and primary cul-
tures, 2 μg of cDNA was incubated with: 10 μL of Fast
SYBR green master mix (Cat no. 4385612, Applied Bio-
systems, USA), 7 μL of nuclease free water, 1 μL of
primers (250 nM, IDT, USA). All of the amplifications
obtained had a unique peak for each PCR product. The
sequence of each primer set used is shown below in
Table 2. To perform this analysis we used the 7500 fast
real-time PCR system (Applied Biosystems, USA). For
the analysis the program consisted of an initial step of
95°C for 20 sec, then 40 cycles of 3 sec at 95°C and an
annealing/extension step of 30 sec at 60°C in which the
reporter signal was acquired. The melting curve was
formed by: 95°C for 15 sec, followed by 1 min at 60°C,
then 30 sec at 95°C and finally 15 sec at 60°C. The
values obtained were normalized relative to HPRT1
levels and then the results were graphed using the
method of 2-( ΔCt), data is represented as the log of the
mean relative to control.
Statistical analysis
The statistical analysis was performed using GraphPad
Prism 5 software (GraphPad, Inc., San Diego, CA). The
results are expressed as means ± standard deviations.
The differences in the results showed in the scratch and
chemoattractant assays were analyzed using ANOVA test
with Bonferroni Post-test. The differences in the results
showed in the levels of MICs markers and TF, and in
number of spheres were analyzed using the student’s t test.
P values of <0.05 were considered statistically significant.
Results
Immunofluorescence using a platelet specific CD42b
antibody (that reacts with platelet GPIb) demonstrated
that platelets are present together with cancer cells in
peritoneal fluid extracted from an ovarian cancer patient
(Figure 1). The merge with vimentin antibody and
Hoechst stain shows that the platelets associate with
cancer cells (see also immunofluorescence negative con-
trol in Additional file 1: Figure S1). Furthermore, flow
cytometer analysis of ascites extracted from individual
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this fluid (see Additional file 2: Figure S2).
All patient information is confidential and thus coded
for scientific use. We assigned patient numbers (e.g. pa-
tient 5) to cancer cell populations isolated from individ-
ual patients to allow comparison of results between the
different assays used in the paper. Due to limited cell
numbers, not all experiments could be performed for
each patient. After confirming that platelets are present
together with cancer cells, we moved to an in vitro
model to determine the effect of platelets on primary
cultures of advanced ovarian cancer cells. The co-
culture of ascites from 5 separate advance ovarian cancer
patients for 12 hours with 150,000 platelets/uL (physio-
logical concentration) resulted in a marked change in can-
cer cell phenotype, with the occurrence of cell elongation
and a more stromal appearance (Figure 2). It was noted
that the majority of platelets become activated upon con-
tact with cell culture medium (please refer to Additional
file 3: Figure S3). The change in phenotype was present in
each patient culture tested, however different degrees of
phenotypic change were noted (compare patient 2 and 4
with patient cultures 3, 5 and 6) (Figure 2). This was
also reflected in ovarian cancer cell lines treated in the
same manner, where SKOV3 had subtle changes,
whereas UCI101 showed a rapid and notorious pheno-
typic alteration.
Given that the fibroblastic phenotype has been corre-
lated with migratory potential, we tested if platelet pres-
ence enhanced cell motility. The scratch assay disclosed
an enhanced ovarian cancer cell migration at 12 and
24 hours post-addition of platelets (Figure 3). Cell cycleFigure 1 Platelets are present in ascites from ovarian cancer patients. Repr
ovarian cancer patients. Platelet presence is shown by the platelet specific
(Panel A), Hoechst stain (Panel C) and merged image (panel D). Image (4analysis by flow cytometry demonstrated that the
platelet-mediated increase in migration was not a result
of increased cancer cell proliferation (please refer to
Additional file 4: Figure S4). Interestingly, during the
course of these migration assays we visually observed
that the cancer cells (especially in the UCI101 cell line)
appeared to be attracted to platelet aggregates that had
formed in the culture plate. This is shown at different
magnifications (Figure 3E), where the ovarian cancer
cells nearest to the platelet aggregate are more elon-
gated. To test the hypothesis that platelets have chemo-
attractant capacity, we performed migration assays using
Boyden chambers. In this experiment ovarian cancer
cells SKOV3 (Figure 4A), UCI101 (Figure 4B) or primary
cultured ascites cells (Patient 5, Figure 4C), were placed
with platelets in either the upper chamber or in the
lower chamber below the polycarbonate membrane and
not in contact with the cancer cells. As shown in each of
the three experiments, an increase in migration to the
lower side of the polycarbonate membrane was only ob-
served when the platelets were used as a chemoattract-
ant, independent of platelet-induced phenotype changes
(Figure 2).
To analyze further the phenotype change we examined
at the transcript and protein level genes known to be as-
sociated with a MIC and EMT phenotypes. In both cell
lines tested, platelet co-culture for 6 hours increased
CD44 and N-Cadherin mRNA levels. E-Cadherin was
barely detectable in UCI101, but was decreased in
SKOV3 (Figure 5A and B). This mRNA change was also
reflected at the protein level, as demonstrated by repre-
sentative blots (Figure 5C), and in its quantificationesentative immunofluorescence from a smear of ascites obtained from
antibody CD42b (green, panel B) and merged with vimentin antibody
0X).
Figure 2 Platelets modify ovarian cancer cell phenotype. Light microscope images (20X) of ascites primary cultures and ovarian cancer cell lines
co- cultured with or without platelets (150,000/μL) during 12 hours.
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markers Snail and Twist was also observed in SKOV3
cells and primary cultured cancer cells (please refer to
Additional file 5: Figure S5).
Culture of the ovarian cancer cell line UCI101 in basal
medium was used to form cancer spheres in the pres-
ence and absence of platelets. Isolated spheres were se-
lected on the basis of size and were confirmed to
demonstrate increased expression of CD44 by immuno-
cytochemistry and expression of EMT protein markers
by Western blotting (please refer to Additional file 5:
Figure S5). Spheres formed under both conditions; how-
ever their number was greatly enhanced in the presence
of platelets (Figure 5E and F).
Platelet interaction with tumor cells increased TF
mRNA at 6 hours (Figure 6A) and the correspondingprotein levels at 12 and 24 hours (Figure 6B and C, for
SKOV3 and UCI101, respectively). β-Actin expression in
these conditions is also increased due to the presence of
platelets (Figure 6B and C). To control for this we evalu-
ated the nuclear protein Histone 3 which is not
expressed by platelets (Figure 6B and C) as a loading
control for the levels of cancer cell proteins. This in-
crease in TF protein upon platelet interaction was also
observed in cells isolated form spheres (Figure 6D). By
flow cytometry we observed that in the whole cell
UCI101 population 40% of the cells expressed TF. Of
the population of UCI101 cells that formed spheres, only
8% expressed this protein, however this percentage in-
creased to 22% in sphere cells that formed in the pres-
ence of platelets. The increase of TF protein in tumor
cells was associated with an enhanced TF-mediated FXa
Figure 3 Platelet enhance ovarian cancer cell migration. Scratch assay of ovarian cancer cell lines treated with or without platelets (150,000/μL).
A and C: SKOV 3 and UCI101 images (10X) of scratches at 0, 12, 24, 36 or 48 hours. B and D quantification of the percentage of area respect to
the initial scratch area (Image J) N = 3; ***p < 0.001 respect to control, ANOVA with Bonferroni as Post- test. E: Light microscope image (10x) of
the interaction between platelets and UCI cells after 12 hours of co-culture with platelets.
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Figure 4 Platelets act as a chemoattractant to enhance ovarian
cancer cell migration. Effect of platelets on migration and
chemotaxis assays performed in SKOV3, UCI101 and primary cultured
cancer cells obtained from ovarian ascites (Patient 10). A, B and C
shows the number of cells that migrated under “Control” (no platelets
added), “Upper” (platelets added within the cells) or “Lower” conditions
(platelets added in the lower chamber) N = 3 for cell lines, **p < 0.01
relative to control, ANOVA with Bonferroni as Post- test.
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(Figure 6E). Despite platelets having been reported to
express functional TF [31] our antibody did not detectTF protein in the platelet lysates (Figure 6B and C).
Analyzing the ovarian cancer line A2780 that does not
express TF, we observed no changes in procoagulant
activity (Figure 6E) after incubation with platelets. The
tissue factor pathway inhibitor (TFPI-1) inhibited the
increase in coagulation in SKOV3 and UCI101 cells
demonstrating that TF was responsible for the platelet-
mediated increase in coagulation (Figure 6E).
To demonstrate that the changes in TF and MIC/
EMT markers with platelets were not a cell line artifact,
we obtained primary cultures of ovarian cancer cells
from eight separate patients. After 6 hours of platelet
addition to these cancer cells we observed an increase in
TF and CD44, with a decrease in E-Cadherin in all pa-
tients. An increase in N-Cadherin was observed in 5 of
the 8 patients (Figure 7A). Although in many primary
cultures not enough cells were recovered for western
blotting, we demonstrate that these changes at the level of
mRNA were also reflected at the protein level (Figure 7B).
Interestingly, primary culture of a benign ovarian fibrothe-
coma (Patient 7, Figure 7A), a benign ovarian mucinous
cystadenoma (Patient 10, Figure 7A) and a primary periton-
eal carcinomatosis (Patient 4, Figure 7A), demonstrated
that platelet-induced regulation of E-Cadherin, TF and
CD44 was not limited to only malignant ovarian cancers.
Furthermore, in three of three patients analyzed we ob-
served a platelet-mediated increase in the EMT-related pro-
teins Twist and Snail (Figure 7B). Finally, to evaluate if the
effects observed by platelets are exclusively due to the pres-
ence of platelet membrane or whether factors released from
the platelets (or membrane associated factors) are required,
we denatured the platelets by heating to 95°C before
addition to the culture medium. As observed in Figure 8A,
denatured platelets are incapable elevating CD44 and
N-Cadherin, or decreasing E-Cadherin protein levels
in ovarian cancer cells. The platelet-induced change
in phenotype of ovarian cancer cells was also lost
(Figure 8B).
Discussion
Metastasis is not solely a function of the tumor cells.
The cancer cell requires an intricate coordination with
its immediate environment, the site of extravasation and
the host tissue (reviewed in [32]). The observation that
cancer cells come into contact with platelets has been
already established. Confocal microscopy analysis of leio-
myosarcoma and histiocytoma tumors has demonstrated
the presence of platelets and activated platelets within
the tumor mass [33]. In a mouse cancer model, platelets
expressing yellow fluorescent protein (YFP) isolated
from female transgenic C57BL/6 mice were transfused
by tail-vein injections into ovarian tumor-bearing mice.
The presence of extravascular YFP platelets was ob-
served in both ascites and tumor specimens [17].
Figure 5 Platelets increase MICs marker levels and ovarian cancer sphere formation. mRNA levels in respect to control of SKOV3 (Panel A) and
UCI101 (Panel B) cell co-cultured during 6 hours with platelets (150,000/μL, N = 3). Data is represented as the log of the mean relative to control.
Representative images of protein levels of ovarian cancer cell lines after 12 hours of co-culture with platelets (Panel C) with quantification in
panel D (N = 3) representative images of ovarian cancer spheroids (spheres) formed by UCI101 cells in the presence and absence of platelets
(Panel E), with quantification shown in Panel F (N = 3), right: quantification of the total number of spheres counted *p < 0.05 ; **p < 0.01;
***p < 0.001, student t-test.
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and enters the blood stream platelet-cancer cell inter-
action becomes inevitable. Preclinical data suggest that
cancer cell-platelet interaction in the blood facilitates
tumor metastasis. These platelets may form aggregates
with circulating tumor cells and physically act as a shield
for the host immune surveillance [34]. A report by Stone
and colleagues (2012) demonstrated a median time to
disease progression of 4.65 years in patients withoutthrombocytosis, as opposed to 2.62 years in patients pre-
senting more than 450,000 platelets/uL [17].
The platelet concentration present in ascites is difficult
to ascertain, as platelets entering the peritoneal cavity
would be expected to adhere to collagen in the periton-
eal wall. In fact, in mouse models it has been shown that
circulation-derived platelets adhere to the peritoneum
surface [17]. We also see that a high proportion of the
platelets that enter the ascites are bound to cancer cells
Figure 6 Platelets increase Tissue Factor (TF) levels. A: Levels of mRNA relative to control of ovarian cancer cell lines SKOV3 and UCI101 co-cultured
with platelets for 6 hours (N = 3). B and C: Western blot analysis of cell lines SKOV3 and UCI101 co-cultured with platelets during 12 or 24 hours. Above:
density analysis of western blot bands respect to H3 levels. (N = 3). D: Flow cytometry analysis of TF levels of ovarian cancer spheroid of UCI101 cells
formed in presence or absence of platelets (N = 3) E: Procoagulant activity assay (units of FXa formed) of ovarian cancer cell lines cultured during 24 h
with or without platelets (N = 3). *p < 0.05; **p < 0.01; ***p < 0.001 respect to control, student´s t-test.
Orellana et al. BMC Cancer  (2015) 15:290 Page 11 of 15(Figure 1). For these reasons we utilized normal circulat-
ing concentrations of platelets in our studies. Further-
more, this concentration of platelets allows us to
extrapolate our proposed model to cancer cells entering
the blood stream.
It has been convincingly demonstrated that the plate-
let addition to tumor cells can induce an invasivemesenchymal-like phenotype and that platelets can
prime the tumor cells for metastasis [20]. Herein, we
take this story a step further, demonstrating that this
also occurs in ovarian cancer cell lines and in primary
cultured cancer cells extracted directly from patients. In
accordance with previous reports in the literature, our
platelets underwent activation upon contact with the
Figure 7 Platelets modify MIC marker and TF levels of primary cultured cancer cells extracted from the ascites of ovarian cancer patients.
A: mRNA levels of MICs markers and TF over control of 8 patient samples cultured with or without platelets for 6 hours. Data is represented as
the log of the mean in respect to control. B: Western blot analysis of N-Cadherin, TF, Twist, Slug and Snail in primary cultures treated with or
without platelets during 12 hours. Protein yields were not sufficient to analyze all proteins in the primary cultures.
Orellana et al. BMC Cancer  (2015) 15:290 Page 12 of 15cancer cell cultures and we also detected high levels of
platelet activation in patient ascites (Additional file 2:
Figure S2 and Additional file 3: Figure S3) [35]. In all
patient-derived cancer cells (8 patients) we found a reduc-
tion in E-Cadherin and an increase in the stem cell marker
CD44 and TF protein upon exposure to platelets. This loss
in E-Cadherin may be due to the platelet-mediated in-
crease in Twist and Snail observed in Figure 7 [10-12].
We are not aware of previous reports describing increases
of CD44 and TF after platelet exposure in ovarian cancer.
We have previously demonstrated in breast cancer cells
that increased TF expression is associated with enhanced
cancer cell migration [25]. CD44 and a stemness pheno-
type have also been reported by others to increase migra-
tion and invasion [36-40]. Accordingly, in this manuscript
we demonstrated statistical differences in migration of
ovarian cancer cells upon exposure to platelets (Figure 3).
An increase in migration by platelets has been observed
previously in pancreatic cancer cell lines and this effect
was reduced by the antiplatelet cilostazol [41]. However, a
strikingly novel observation of our study was the attractionof ovarian cancer cells to platelet aggregates. In Boyden
chambers we showed that the presence of platelets below
the tumor cells caused enhanced migration across the poly-
carbonate membrane, thus a physical movement of tumor
cells towards the platelets. This suggests that along with a
change in EMT markers, the observed change in phenotype
may be a result of cells migrating towards platelets.
Interestingly, the ability of platelets to mediate cancer
cell proliferation has been demonstrated in the litera-
ture, however the majority of our observations were per-
formed at time points below the doubling time of these
cancer cell lines [42]. We demonstrate at the 12 hours
time point used in the migration assay that there was no
change in cell cycle upon platelet addition (Additional
file 4: Figure S4) and thus we speculate that platelets in-
crease the migration of ovarian cancer cells through che-
moattraction. Whether the expression or EMT and/or
TF are involved in this chemoattraction is still unknown.
Interestingly, the presence of the platelets above the can-
cer cells did not increase a downward migration, despite
an increase in lateral migration being observed in the
Figure 8 Denatured platelets do not alter protein levels or bring
about a phenotypic change in ovarian cancer cells. A. Representative
Western blots of SKOV3 and UCI101 cells co-cultured during 24 hours
with either vehicle, platelets (150,000/μL) or platelets heated to 95°C
for 5 minutes prior to addition. B. Representative light microscope
images (20X) of primary cultured cancer cells (patient 13) co-cultured
for 12 hours with either vehicle, platelets (150,000/μL) or platelets
heated to 95°C for 5 minutes prior to addition to culture medium.
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the movement is towards the platelets (chemoattraction).
In the scratch assay we did notice enhanced migration
when a platelet aggregate was in the scratch area. The
possibility that platelets can be chemoattractant to can-
cer cells in vivo raises several questions. Could platelet
accumulation at sites of vascular injury attract or cap-
ture cancer cells in circulation? Once at this site, could
the enhancement of EMT markers and TF promote
extravasation? These questions may be also valid in the
opposite direction; platelets at areas of vascular injury or
poor vascular integrity (as often observed in tumors),
could attract cancer cells to escape from the primary
tumor and migrate towards the vasculature and thus be-
come metastatic. These scenarios seem attractive in the
setting of ovarian cancer where it is known that ascites
derived platelets adhere to the peritoneal membrane,
where the metastatic foci of ovarian cancer occurs.
Platelets contain many molecules with attractant prop-
erties, such as PDGF [43] or TGFβ [44], among others,
that may play a role in this effect. Platelets have also
been shown to liberate microparticles that could be play-
ing a direct role upon the cancer cells [45]. Although wedemonstrate that denatured platelets cannot bring about
a change in phenotype and EMT marker protein expres-
sion, further experiments are required to elucidate the
pathophysiological contribution of platelet-induced at-
traction in the development of metastasis. However,
platelet-derived TGFβ1, together with other platelet-
bound factors have been shown to cooperate to increase
metastasis. Platelets can activate the NF-κB signaling
pathway in a contact-dependent manner. Interestingly, it
appears that platelet-induced effects on EMT and inva-
sion are not mediated by secreted TGFβ alone, but
require additional platelet-bound factors [20].
An approach to identify MICs in vitro is through the
use of sphere-forming assays. Under special culture condi-
tions, a subset of a cancer cell line or primary tumor
population cells are able to form three-dimensional spheres,
demonstrate enrichment in stem cell markers and display
the capability of anchorage-independent growth. CD44-
positive spheres isolated from ovarian serous adenocarcin-
omas by this technique have been shown to form tumors
more efficiently in animal models [13]. Using this method
we noted that the presence of platelets enhanced the num-
ber of spheres formed. In the whole cell population of the
UCI101 ovarian cancer cell line, 40 % of these cells
expressed TF. Only 8% for the spheres that formed
expressed TF, however in the presence of platelets the frac-
tion of TF-expressing spheres increased to 22%. The repre-
sentation of a “metastasis initiating cell” with a rigid
definition of protein markers is a concept that is mostly
likely going to change. Of the numerous MICs that leave
the primary tumor, most probably only a few of these are
capable of forming secondary tumors. It is also likely that
the MICs that survive to form metastatic foci change the
expression of their cell surface proteins numerous times be-
fore the establishment of metastatic foci. For example, the
presence of TF may or may not be necessary for the MIC
to leave the primary tumor, but it may be necessary to
cause localized coagulation to recruit more platelets to
shield the cancer cell from the immune system [46].
Strengthening this theory, it has been reported that pre-
operative serum TF levels of ovarian cancer patients are
around 85.2 pg/mL, significantly higher than levels found
in patients with low malignant potential tumors (12.8 pg/
mL) [47]. A further role of TF, either alone or in its com-
plex, maybe to act as a ligand or tether for endothelial-
anchored TFPI-1. The interaction of TF-TFPI-1 may act to
halt the cancer cell in circulation and favor extravasation
[48]. Although the consequence of a platelet-induced gain
of TF in MICs (in this case 8% to 22%) is unknown, it may
contribute to the clinical observation correlating platelet
levels to an increase in cancer metastasis [21].
In summary, we report for the first time that platelets
are present together with cancer cells in peritoneal asci-
tes from ovarian cancer patients. We show that platelets
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MIC markers in ovarian cancer cells. Finally we demon-
strate that platelets can act as a chemoattractant to cancer
cells. This data complements the existing concept that
platelets may be an interesting target for future cancer
therapies.
Conclusions
 Platelets potentiate a phenotypic change in ovarian
cancer cells, inducing MIC (EMT/stem cell) markers
 Platelets act as chemoattractants to ovarian cancer cells
 Platelets promote ovarian cancer sphere formation.
 Platelets increase Tissue Factor, mRNA, protein and
coagulating function.Additional files
Additional file 1: Immunofluorescence negative control of CD42b.
Representative immunofluorescence from a smear of ascitic fluid
obtained from ovarian cancer patients. (A) Absence of primary antibody
CD42b (B) Vimentin staining in absence of primary antibody CD24b (C)
Nuclear Hoechst staining.
Additional file 2: Activated platelets are present in ascites from
ovarian cancer patients. Flow cytometry analysis of CD61 of human
ascites extracted from ovarian cancer patients. (A) Number of platelets
detected (B) Representative plot of ascites content. Platelet events are
surrounded by discontinuous line (C) Flow cytometry analysis of CD62P
expressed in activated platelets of human ascites extracted from ovarian
cancer patients.
Additional file 3: Platelets activation upon contact with the culture
medium. This graph demonstrates that the vast majority of the platelets
added to each experiment become activated upon contact with the
culture medium. This is not surprising, as it is known that platelets in the
blood stream remain in an inactivated form due to the presence of
inhibitors. We speculate that these inhibitors are diluted out once the
platelets are placed in culture medium. However, it is also speculated
that the activated platelets can possess growth factors (eg TGFbeta) that
are anchored to the membrane and thus are not released. These require
platelet-cancer cells interaction, where the cancer cells proteases can
cleave the growth factors permitting a slow, maybe sustained, release.
*p<0.05 with respect to control. N=3, Anova con Bonferroli post-test.
There is no significant differences between the treatment conditions.
Additional file 4: Platelet presence does not alter the proliferation
of the SKOV3 ovarian cancer cell line. Cancer cell were treated with or
without platelets (150,000/μL) for 12 hours before cell cycle evaluation by
propidium iodide staining and flow cytometry analysis (M1, sub GO/GI
(cell death). M2, GO/G1. M3, S/G2/M). Platelet presence produced no
significant difference in cell cycle distribution. Each set of graphs (N)
represents an independent experiment.
Additional file 5: Ovarian cancer sphere isolation and
characterization. UCI101 ovarian, were cultured in 6 well low
attachment plates in DMEM/F12 medium supplemented with FGF 50 ug/
mL; EGF 0.2 mg/mL; insulin 5g/mL. Every 48 hours 1mL of supplemented
medium with or without 1.5 105 platelets uL-1 was added. After 7 day of
culture, medium was passed through a strainer to select cancer spheres
clusters of less than 100 μm. Spheres were recuperated and analyzed by
immunocytochemistry in the presence and absence (negative control) of
anti-CD44 antibody (A). Western blot analysis (B) and subsequent quantification
(C) demonstrated an increase in CD44 and EMT markers and a decease
in E-Cadherin in respect to the parental cell line (total population). Student
t-test ,*p>0.05 respect to control, **p>0.01 respect to control (three
independent experiments).Abbreviations
EMT: Epithelial-mesenchymal transition; CD44: Also referred as homing cell
adhesion molecule (HCAM); TF: Tissue factor; TGFβ: Transforming growth
factor-beta; VEGF: vascular endothelial growth factor; PDGF: platelet–derived
growth factor; Smad: Transcription factor that transduce extracellular signals
from transforming growth factor beta ligands to the nucleus; NF-κB: Nuclear
factor kappa-light-chain-enhancer of activated B cells (Transcription factor);
CD42b: Cluster of differentiation 42b; GPIb: Platelet glycoprotein Ib;
TFPI: Tissue factor pathway inhibitor; YFP: Expressing yellow fluorescent
protein; PGE1: Prostaglandin E1; RT-PCR: Reverse transcription polymerase
chain reaction.
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